Cisplatin, gemcitabine, vinorelbine (PGV) vs cisplatin and gemcitabine (PG) vs cisplatin, gemcitabine, paclitaxel (PGT) in advanced NSCLC:: Final analysis a phase III trial

被引：0
|
作者：
Comella, G [1 ]
Frasci, G [1 ]
Panza, N [1 ]
Nicolella, G [1 ]
Manzione, I [1 ]
De Cataldis, G [1 ]
Cioffi, R [1 ]
Micillo, E [1 ]
Lorusso, V [1 ]
Bilancia, D [1 ]
Maiorino, L [1 ]
Piantedosi, FV [1 ]
Mangiameli, A [1 ]
Gravina, A [1 ]
Lamberti, A [1 ]
De Lena, M [1 ]
Comella, P [1 ]
机构：
[1] Tumor Inst Naples, So Italy Cooperat Oncol Grp, Naples, Italy
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A10
引用
收藏
页码：3 / 3
页数：1
相关论文
共 50 条
  • [21] Phase II trial of gemcitabine, paclitaxel, and cisplatin in advanced transitional cell carcinoma.
    Clark, PE
    Stindt, D
    Hall, MC
    Harmon, M
    Lovato, JF
    Mohler, R
    Kimbrough, C
    Torti, FM
    JOURNAL OF UROLOGY, 2005, 173 (04): : 360 - 360
  • [22] Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer
    Roth J.A.
    Carlson J.J.
    Journal of Gastrointestinal Cancer, 2012, 43 (2) : 215 - 223
  • [23] Gemcitabine plus vinorelbine(GV) vs. gemcitabine plus paclitaxel(GT) vs. gemcitabine(G) vs. paclitaxel(T) in elderly NSCLC patients
    Frasci, G
    Lorusso, V
    Cornella, P
    Panza, N
    Nicolella, G
    Bianco, A
    De Cataldis, G
    Belli, M
    Iannelli, A
    Massidda, B
    Mancarella, S
    Masullo, P
    Comella, G
    De Luna, M
    ANNALS OF ONCOLOGY, 2000, 11 : 6 - 6
  • [24] Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial
    Reni, M
    Cordio, S
    Milandri, C
    Passoni, P
    Bonetto, E
    Oliani, C
    Luppi, G
    Nicoletti, R
    Galli, L
    Bordonaro, R
    Passardi, A
    Zerbi, A
    Balzano, G
    Aldrighetti, L
    Staudacher, C
    Villa, E
    Di Carlo, V
    LANCET ONCOLOGY, 2005, 6 (06): : 369 - 376
  • [25] Significantly higher survival with Gemcitabine-cisplatin vs cisplatin in advanced non-small cell lung cancer (NSCLC): Final results from an international randomized phase III study
    Sandler, A
    Denham, C
    von Pawel, J
    Cormier, Y
    Gatzemeier, U
    Mattson, K
    Manegold, C
    Gregor, A
    Blatter, J
    Einhorn, L
    ANNALS OF ONCOLOGY, 1998, 9 : 85 - 85
  • [26] Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial
    不详
    LANCET ONCOLOGY, 2008, 9 (01): : 39 - 44
  • [27] Tislelizumab plus cisplatin/carboplatin and gemcitabine versus placebo plus cisplatin/carboplatin and gemcitabine in Chinese patients with advanced urothelial carcinoma: A phase III trial in progress
    Bi, Feng
    Li, Han-Zhong
    Zhu, Shaoxing
    Zou, Qing
    Tang, Jia
    Zhang, Wei
    Ye, Dingwei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [28] EGFR IHC and FISH Correlative Analyses (SQUIRE Trial): Necitumumab plus Gemcitabine-Cisplatin vs Gemcitabine-Cisplatin in 1st-Line Squamous NSCLC
    Hirsch, Fred R.
    Boyle, Theresa A.
    Thatcher, Nick
    Paz-Ares, Luis
    Varella-Garcia, Marileila
    Kowalewski, Ashley A.
    Hozak, Rebecca R.
    Mi, Gu
    Melemed, Symantha A.
    Caldwell, Charles W.
    Kurek, Raffael
    Socinski, Mark A.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S797 - S797
  • [29] Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in the treatment of advanced non-small cell lung cancer (NSCLC).
    Zhang, Y
    Zhang, L
    Li, N
    Xu, F
    Pan, ZK
    Guang, ZZ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 702S - 702S
  • [30] LIPOPLATIN PLUS GEMCITABINE VERSUS CISPLATIN PLUS GEMCITABINE AS FIRST-LINE TREATMENT AGAINST NSCLC: INTERIM ANALYSIS OF A PHASE III TRIAL
    Mylonakis, N.
    Athanasiou, A.
    Angel, J.
    Lampaki, S.
    Kosmas, C.
    Rapti, A.
    Ziras, N.
    Politis, N.
    Kottaridis, S.
    Boulikas, T.
    ANTICANCER RESEARCH, 2008, 28 (5C) : 3358 - 3359
12345